Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Outsourcing

Piramal will buy Indian peptide maker Hemmo

by Michael McCoy
April 3, 2021 | A version of this story appeared in Volume 99, Issue 12

 

Piramal Pharma Solutions has agreed to acquire Hemmo Pharmaceuticals, an Indian producer of synthetic peptides, for about $106 million. Piramal, which provides active pharmaceutical ingredient and finished-drug manufacturing services, says the purchase will take it into the peptide production business. The firm calls Hemmo one of the world’s few pure-play synthetic peptide makers.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.